3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Neoplasms
5
Lung Neoplasms
4
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Hematologic Neoplasms
2
Solid Tumors
1
Neuroblastoma
1
Neoplasms, Unknown Primary
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 2a
1
Lymphoma
1
Lung Diseases
1
Genomic Instability
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Bone Neoplasms
1
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
1
ALK+ Advanced NSCLC
1
Interventions
Cyclophosphamide
8
Rituximab
5
fludarabine
4
Vincristine
4
Prednisone
4
Doxorubicin
4
fludarabine phosphate
3
Tacrolimus
3
Mycophenolic Acid
3
Etoposide
3
Busulfan
3
venetoclax
2
entrectinib
2
atezolizumab
2
alectinib
2
acalabrutinib
2
Whole-Body Irradiation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Bortezomib
2
trametinib
1
pertuzumab
1
pembrolizumab
1
obinutuzumab
1
liposomal doxorubicin
1
isatuximab
1
ibrutinib
1
etoposide phosphate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
alectinib
×
1 year
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled